

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

It was raised during scoping that there are inconsistencies between devolved nation decisions on the provision of abiraterone and that this could lead to inequalities by geographical UK region. For example, abiraterone is available in Scotland, but not in England.

It was also raised that prostate cancer is a condition that can only affect people with a prostate, and therefore men and others assigned male at birth.

NICE's remit covers the NHS in England and therefore cannot make recommendations on how abiraterone is used in devolved nations. However, the recommendation that abiraterone can be used (in England) is expected to address the issue raised.

The recommendation includes use of abiraterone for any adults with newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (within its marketing authorisation) and does not restrict based on gender, including gender reassignment.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Not applicable

Approved by Associate Director (name):Richard Diaz.....

Date: 6 October 2025